JPWO2019237065A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019237065A5 JPWO2019237065A5 JP2021518059A JP2021518059A JPWO2019237065A5 JP WO2019237065 A5 JPWO2019237065 A5 JP WO2019237065A5 JP 2021518059 A JP2021518059 A JP 2021518059A JP 2021518059 A JP2021518059 A JP 2021518059A JP WO2019237065 A5 JPWO2019237065 A5 JP WO2019237065A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- iodide
- subject
- injury
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 45
- 208000014674 injury Diseases 0.000 claims description 32
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 29
- 208000027418 Wounds and injury Diseases 0.000 claims description 25
- 230000006378 damage Effects 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 230000004064 dysfunction Effects 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 8
- 208000037816 tissue injury Diseases 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- 150000002366 halogen compounds Chemical class 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000000451 tissue damage Effects 0.000 claims description 5
- 231100000827 tissue damage Toxicity 0.000 claims description 5
- 208000010444 Acidosis Diseases 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000035902 Critical illness myopathy Diseases 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 208000007882 Gastritis Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 206010051606 Necrotising colitis Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 4
- 206010036105 Polyneuropathy Diseases 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 206010066336 critical illness polyneuropathy Diseases 0.000 claims description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 4
- 208000037920 primary disease Diseases 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 3
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 claims description 2
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 206010029315 Neuromuscular blockade Diseases 0.000 claims description 2
- 208000019155 Radiation injury Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010039163 Right ventricular failure Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 229910021612 Silver iodide Inorganic materials 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 230000007950 acidosis Effects 0.000 claims description 2
- 208000026545 acidosis disease Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000020538 atrophic muscular disease Diseases 0.000 claims description 2
- 230000003935 attention Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229910001640 calcium iodide Inorganic materials 0.000 claims description 2
- 229940046413 calcium iodide Drugs 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000006443 lactic acidosis Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 claims description 2
- 229910001641 magnesium iodide Inorganic materials 0.000 claims description 2
- 230000015654 memory Effects 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 201000010384 renal tubular acidosis Diseases 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 229940045105 silver iodide Drugs 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000012929 tonicity agent Substances 0.000 claims description 2
- 230000008359 toxicosis Effects 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 210000004165 myocardium Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682574P | 2018-06-08 | 2018-06-08 | |
| US62/682,574 | 2018-06-08 | ||
| US201862730927P | 2018-09-13 | 2018-09-13 | |
| US201862730945P | 2018-09-13 | 2018-09-13 | |
| US62/730,945 | 2018-09-13 | ||
| US62/730,927 | 2018-09-13 | ||
| PCT/US2019/036154 WO2019237065A1 (en) | 2018-06-08 | 2019-06-07 | Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527130A JP2021527130A (ja) | 2021-10-11 |
| JP2021527130A5 JP2021527130A5 (https=) | 2022-05-13 |
| JPWO2019237065A5 true JPWO2019237065A5 (https=) | 2022-05-13 |
Family
ID=68770655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518059A Pending JP2021527130A (ja) | 2018-06-08 | 2019-06-07 | 組織傷害および集中治療後症候群の処置および予防のためのハロゲン化合物の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210252047A1 (https=) |
| EP (1) | EP3801565A4 (https=) |
| JP (1) | JP2021527130A (https=) |
| KR (1) | KR20210018898A (https=) |
| CN (1) | CN112469422A (https=) |
| AU (1) | AU2019282820A1 (https=) |
| CA (1) | CA3102792A1 (https=) |
| IL (1) | IL279221A (https=) |
| MX (1) | MX2020013306A (https=) |
| WO (1) | WO2019237065A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386702B (es) | 2014-02-10 | 2025-03-19 | Fred Hutchinson Cancer Center | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248335B1 (en) * | 1997-10-29 | 2001-06-19 | Symbollon Corporation | Stabilized oral pharmaceutical composition containing iodide and iodate and method |
| CZ295765B6 (cs) * | 1998-07-29 | 2005-10-12 | Apa - Praha, S.R.O. | Léčebný přípravek s virucidním účinkem |
| GB0525504D0 (en) * | 2005-12-14 | 2006-01-25 | Bristol Myers Squibb Co | Antimicrobial composition |
| MX386702B (es) * | 2014-02-10 | 2025-03-19 | Fred Hutchinson Cancer Center | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. |
-
2019
- 2019-06-07 US US16/972,718 patent/US20210252047A1/en not_active Abandoned
- 2019-06-07 WO PCT/US2019/036154 patent/WO2019237065A1/en not_active Ceased
- 2019-06-07 EP EP19814153.3A patent/EP3801565A4/en not_active Withdrawn
- 2019-06-07 MX MX2020013306A patent/MX2020013306A/es unknown
- 2019-06-07 CN CN201980049776.3A patent/CN112469422A/zh active Pending
- 2019-06-07 KR KR1020217000098A patent/KR20210018898A/ko not_active Ceased
- 2019-06-07 AU AU2019282820A patent/AU2019282820A1/en not_active Abandoned
- 2019-06-07 CA CA3102792A patent/CA3102792A1/en active Pending
- 2019-06-07 JP JP2021518059A patent/JP2021527130A/ja active Pending
-
2020
- 2020-12-06 IL IL279221A patent/IL279221A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Setten et al. | Prone position in patients with acute respiratory distress syndrome | |
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| JP2019206562A5 (https=) | ||
| JP2020520963A5 (https=) | ||
| JP2014532726A5 (https=) | ||
| JP2020529440A5 (https=) | ||
| US20210283049A1 (en) | Intravenous sotalol hydrochloride loading and maintenance for cardiac surgery patients | |
| JP2021532176A5 (https=) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2012533542A5 (https=) | ||
| JPWO2019237065A5 (https=) | ||
| Xiao et al. | Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study | |
| JP2021535171A (ja) | 解糖依存的な病態、特に癌を治療するための乳酸塩保護低血糖 | |
| JP2021527130A5 (https=) | ||
| Kambam et al. | Histamine2 receptor blocker in the treatment of protamine related anaphylactoid reactions: two case reports | |
| US20230241078A1 (en) | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | |
| JP2018537522A (ja) | 組合せ | |
| US20170165280A1 (en) | Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof | |
| Frenkel et al. | Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy-Case Report | |
| TW200409643A (en) | Preventive agents for diabetes mellitus | |
| CN104000814B (zh) | 一种防治痛风性关节炎的药物组合物及其用途 | |
| Clifford et al. | Intensive nitrogen mustard therapy with abdominal aortic occlusion in nasopharyngeal carcinoma | |
| AU2016364380B2 (en) | Formulations for intravenous injection of danirixin | |
| KR102788567B1 (ko) | 16-하이드록시헥사데카노익산을 유효성분으로 포함하는 대사성 질환 치료용 약학적 조성물 | |
| JP2019521184A5 (https=) |